Thalidomide treatment of resistant or relapsed multiple myeloma patients.

Marek Hus(Medical University of Lublin), Joanna Mańko, Anna Dmoszyńska(1 Military Clinical Hospital with Outpatient Clinic), Maria Soroka‐Wojtaszko, Dariusz Jawniak, Andrzej Hellmann(Gdańsk Medical University), Wojciech Legieć, Teresa Wolska-Smoleń, A B Skotnicki, H Ciepnuch

PubMed

April 1, 2001

Cited by 85

Related Papers

Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia

|New England Journal of Medicine|2004|921

Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia

|Journal of Clinical Oncology|2007|556

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

|Leukemia|2015|255

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

|New England Journal of Medicine|2024|162

Therapy‐related peripheral neuropathy in multiple myeloma patients

|Hematological Oncology|2014|70